These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 24743218)

  • 1. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
    Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
    Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
    Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
    Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
    Du Pisani LA; Shires K
    Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
    Ritterhouse LL; Parilla M; Zhen CJ; Wurst MN; Puranik R; Henderson CM; Joudeh NZ; Hartley MJ; Haridas R; Wanjari P; Furtado LV; Kadri S; Segal JP
    Mol Diagn Ther; 2019 Dec; 23(6):791-802. PubMed ID: 31673932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Minimal Residual Disease in Standard-Risk AML.
    Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
    N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.
    Gao MG; Ruan GR; Chang YJ; Liu YR; Qin YZ; Jiang Q; Jiang H; Huang XJ; Zhao XS
    Ann Hematol; 2020 Jan; 99(1):73-82. PubMed ID: 31768677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
    Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
    Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.
    Kassem N; Hamid AA; Attia T; Baathallah S; Mahmoud S; Moemen E; Safwat E; Khalaf M; Shaker O
    J Egypt Natl Canc Inst; 2011 Jun; 23(2):73-8. PubMed ID: 22099964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience.
    El-Gamal RAE; Hashem AE; Habashy DM; Abou Elwafa MAZ; Boshnak NH
    Int J Lab Hematol; 2021 Feb; 43(1):68-75. PubMed ID: 32856429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
    Schnittger S; Kern W; Tschulik C; Weiss T; Dicker F; Falini B; Haferlach C; Haferlach T
    Blood; 2009 Sep; 114(11):2220-31. PubMed ID: 19587375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
    Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
    Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.